My thesis is slightly different as it's not typically dependent on P3 primary trial success and FDA approval to assess the risk of holding PAR.
I think the probability is higher than the market currently expects for a positive (black swan style event) in the form of (1) multi-billion $ partnership deal or (2) complete takeover. If the market doesn't get it and re-rate after IND and 008 then it would be more indicative of a macro risk off trade than my thesis.
Valuation of PAR, page-7
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $288.5K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 130626 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |